

PKA phosphorylates RET:GDNF:GFRA di- mer

Jupe, S., Luo, W., Morales, D.

European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University.

The contents of this document may be freely copied and distributed in any media, provided the authors, plus the institutions, are credited, as stated under the terms of [Creative Commons Attribution 4.0 International \(CC BY 4.0\) License](https://creativecommons.org/licenses/by/4.0/). For more information see our [license](https://www.reactome.org/licenses/).

28/04/2025

Introduction

Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross-referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics researchers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioinformaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways.

The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program).

Literature references

Fabregat, A., Fabregat, A., Fabregat, A., Fabregat, A., Fabregat, A., Fabregat, A. et al. (2017). Reactome pathway analysis: a high-performance in-memory approach. *BMC bioinformatics*, 18, 142. [↗](#)

Sidiropoulos, K., Sidiropoulos, K., Sidiropoulos, K., Sidiropoulos, K., Sidiropoulos, K., Sidiropoulos, K. et al. (2017). Reactome enhanced pathway visualization. *Bioinformatics*, 33, 3461-3467. [↗](#)

Fabregat, A., Fabregat, A., Fabregat, A., Fabregat, A., Fabregat, A., Fabregat, A. et al. (2018). The Reactome Pathway Knowledgebase. *Nucleic Acids Res*, 46, D649-D655. [↗](#)

Fabregat, A., Fabregat, A., Fabregat, A., Fabregat, A., Fabregat, A., Fabregat, A. et al. (2018). Reactome graph database: Efficient access to complex pathway data. *PLoS computational biology*, 14, e1005968. [↗](#)

Reactome database release: 92


This document contains 1 reaction ([see Table of Contents](#))

PKA phosphorylates RET:GDNF:GFRA dimer [↗](#)

Stable identifier: R-HSA-8854908

Type: transition

Compartments: extracellular region, plasma membrane, cytosol



Serine (S) 696 in RET is phosphorylated by protein kinase A. Mutation of this serine almost completely inhibits the ability of RET to activate the small GTPase Rac1 and stimulate formation of cell lamellipodia (Fukuda et al. 2002). Homozygous knock-in mice carrying this mutation lacked enteric neurons in the distal colon, resulting from a migration defect of enteric neural crest cells (Asai et al. 2006). The effects of the S696 RET mutant could be alleviated by simultaneous mutation of Tyrosine-687 (Fukuda et al. 2002). Activation of PKA by forskolin was found to impair the recruitment of SHP2 to RET and negatively affect ligand-mediated neurite outgrowth (Perrinjaquet et al. 2010). Mutation of S696 enhanced SHP2 binding and eliminated the effect of forskolin on ligand-induced neurite outgrowth.

Literature references

Fukuda, T., Takahashi, M., Kiuchi, K. (2002). Novel mechanism of regulation of Rac activity and lamellipodia formation by RET tyrosine kinase. *J. Biol. Chem.*, 277, 19114-21. [↗](#)

Editions

2016-01-25	Authored	Jupe, S.
2016-04-28	Edited	Jupe, S.
2016-05-06	Reviewed	Morales, D.
2016-05-17	Reviewed	Luo, W.